Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tilavonemab - AbbVie/C2N Diagnostics

Drug Profile

Tilavonemab - AbbVie/C2N Diagnostics

Alternative Names: ABBV-8E12; C2N-8E12

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator C2N Diagnostics
  • Developer AbbVie; C2N Diagnostics
  • Class Antibodies; Antiparkinsonians; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progressive supranuclear palsy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Discontinued Progressive supranuclear palsy

Most Recent Events

  • 25 Aug 2022 AbbVie terminates a phase II trial in Alzheimer's disease (Early-stage disease) in Australia, Belgium, Canada, Denmark, Finland, Italy, New Zealand, Netherland, Sweden, Spain and USA due to lack of efficacy in parent study (IV) (NCT02880956)
  • 30 Sep 2021 AbbVie completes phase II clinical trials in Alzheimer's disease (Early-stage disease) the US, Australia, Belgium, Canada, New Zealand and Sweden (IV) in September 2021 (NCT03712787) (EudraCT2018-000268-26)
  • 05 Jul 2021 AbbVie completes phase II clinical trials in Alzheimer's disease (Early-stage disease) in the US, Australia, Belgium, Canada, Denmark, Finland, Italy, New Zealand, Netherland, Sweden and Spain (IV) (NCT02880956)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top